This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Clostridium Difficile Infection
and you are
between 18 and 89
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

A total of 608 participants with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study; participants will receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin.

Provided treatments

  • Drug: CB-183,315
  • Drug: Vancomycin
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01598311. The sponsor of the trial is Cubist Pharmaceuticals LLC and it is looking for 608 volunteers for the current phase.
Official trial title:
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea